Nucala 100mg Injection

Most side effects of Nucala 100mg Injection do not require medical attention as they may disappear as your body adjusts to the medicine. In case these side effects become worse, consult your doctor immediately.

Common side effects include:

• Headache
• Injection site reactions (pain, swelling, redness)
• Back pain
• Fatigue
  

Nucala 100mg is available in injection form and is advised to be taken as per the doctor's prescription. It can only be given by a doctor or nurse under strict medical supervision.

Taking this injection in the wrong way may give you severe side effects. In case of overdose, contact your healthcare provider or doctor and they will provide you with medical attention.

Nucala 100mg Injection is a prescription based medicine with active ingredient Mepolizumab (100mg). It belongs to the monoclonal antibodies class of drugs that work by inhibiting the action of certain natural substances that promote symptoms of asthma like cough, difficulty breathing, chest pain, and wheezing.

• Ortega, H. G., Liu, M. C., Pavord, I. D., Brusselle, G. G., FitzGerald, J. M., Chetta, A., ... & Chanez, P. (2014). Mepolizumab treatment in patients with severe eosinophilic asthma. New England journal of medicine, 371(13), 1198-1207.
  
• Robinson, D. S. (2013). Mepolizumab treatment for asthma. Expert Opinion on Biological Therapy, 13(2), 295-302.
  
• Zanghì, A., Di Filippo, P. S., Rutigliano, C., Avolio, C., & D’Amico, E. (2025). Combined biologic therapy targeting B cells and eosinophils in relapsing multiple sclerosis and severe asthma: a case report of ofatumumab and mepolizumab. Frontiers in Immunology, 16, 1634477.
  
• Bourdin, A., Husereau, D., Molinari, N., Golam, S., Siddiqui, M. K., Lindner, L., & Xu, X. (2020). Matching‐adjusted comparison of oral corticosteroid reduction in asthma: systematic review of biologics. Clinical & Experimental Allergy, 50(4), 442-452.
  
• Ennis, D., Lee, J. K., & Pagnoux, C. (2019). Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Expert Opinion on Biological Therapy, 19(7), 617-630.
  
• Ennis, D., Lee, J. K., & Pagnoux, C. (2019). Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Expert Opinion on Biological Therapy, 19(7), 617-630.​